Sugi Predict

Sugi Predict / Compounds / SCHEMBL17466939

SCHEMBL17466939

SCHEMBL17466939

N#CC(C#N)=Cc1ccc(-c2cccs2)cc1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KMT2A Q03164 8/20 0.57
▸ MEN1 O00255 7/20 0.57
▸ MAPT P10636 7/20 0.57
▸ ALDH1A1 P00352 6/20 0.57
▸ LMNA P02545 4/20 0.57
▸ KDM4E B2RXH2 3/20 0.57
▸ NPSR1 Q6W5P4 2/20 0.57
▸ POLB P06746 2/20 0.57
▸ THRB P10828 1/20 0.50
▸ CISD1 Q9NZ45 1/20 0.50
▸ EGFR P00533 3/20 0.49
▸ HDAC2 Q92769 1/20 0.48
▸ CYP1A2 P05177 2/20 0.45
▸ CYP3A4 P08684 2/20 0.45
▸ HPGD P15428 2/20 0.45
▸ TSHR P16473 2/20 0.45
▸ NFKB1 P19838 2/20 0.45
▸ BLM P54132 2/20 0.45
▸ PMP22 Q01453 2/20 0.45
▸ APEX1 P27695 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17466936 0.78 MAPT (0.85) KMT2AMEN1MAPTALDH1A1LMNA
SCHEMBL17466932 0.75 MAPT (1.00) KMT2AMEN1MAPTALDH1A1LMNA
SCHEMBL6852464 0.75 HDAC2 (0.49) KMT2AMEN1MAPTALDH1A1KDM4E
SCHEMBL6852468 0.75 HDAC2 (0.49) KMT2AMEN1MAPTALDH1A1KDM4E
SCHEMBL17466930 0.74 MAPT (0.71) KMT2AMEN1MAPTALDH1A1LMNA
SCHEMBL13790222 0.74 HDAC2 (0.64) KMT2AMEN1MAPTALDH1A1KDM4E
SCHEMBL28485840 0.73 HDAC2 (0.51) KMT2AMEN1MAPTALDH1A1LMNA
SCHEMBL338810 0.73 LTA4H (0.70) KMT2AMEN1MAPTALDH1A1KDM4E
SCHEMBL6877009 0.72 HDAC2 (0.47) HDAC2CYP3A4LTA4HGSK3BCYP2C9
SCHEMBL6877004 0.72 HDAC2 (0.47) HDAC2CYP3A4LTA4HGSK3BCYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240084308-A1 FIBROTIC TREATMENT MONASH UNIVERSITY (AU) 2024-03-14 — — US disclosed
US-11834663-B2 Fibrotic treatment MONASH UNIVERSITY (AU) 2023-12-05 — — US disclosed
US-11834663-B2 Fibrotic treatment MONASH UNIVERSITY (AU) 2023-12-05 — — US disclosed
US-11834663-B2 Fibrotic treatment MONASH UNIVERSITY (AU) 2023-12-05 — — US disclosed
US-11306066-B2 4H-pyran compounds as insulin-regulated aminopeptidase (IRAP) inhibitors MONASH UNIVERSITY (AU) 2022-04-19 — — US disclosed
US-20210340547-A1 FIBROTIC TREATMENT MONASH UNIVERSITY (AU) 2021-11-04 — — US disclosed
US-20210340547-A1 FIBROTIC TREATMENT MONASH UNIVERSITY (AU) 2021-11-04 — — US disclosed
US-11078488-B2 Fibrotic treatment MONASH UNIVERSITY (AU) 2021-08-03 — — US disclosed
US-11078488-B2 Fibrotic treatment MONASH UNIVERSITY (AU) 2021-08-03 — — US disclosed
EP-3172272-B1 MODIFIED HETEROPHASIC POLYOLEFIN COMPOSITION MILLIKEN & CO (US) 2020-11-25 — — EP disclosed
US-20180170891-A1 4H-Pyran Compounds as Insulin-Regulated Aminopeptidase (IRAP) Inhibitors MONASH UNIVERSITY (AU) 2018-06-21 — — US disclosed
US-20180170891-A1 4H-Pyran Compounds as Insulin-Regulated Aminopeptidase (IRAP) Inhibitors MONASH UNIVERSITY (AU) 2018-06-21 — — US disclosed
EP-3328384-A1 FIBROTIC TREATMENT Monash University (AU) 2018-06-06 — — EP disclosed
EP-3294721-A1 4H-PYRAN COMPOUNDS AS INSULIN-REGULATED AMINOPEPTIDASE (IRAP) INHIBITORS Monash University (AU) 2018-03-21 — — EP disclosed
WO-2017015720-A1 FIBROTIC TREATMENT MONASH UNIVERSITY (AU) 2017-02-02 — — WO disclosed
WO-2017015720-A1 FIBROTIC TREATMENT MONASH UNIVERSITY (AU) 2017-02-02 — — WO disclosed
WO-2016179645-A1 4H-PYRAN COMPOUNDS AS INSULIN-REGULATED AMINOPEPTIDASE (IRAP) INHIBITORS MONASH UNIVERSITY (AU) 2016-11-17 — — WO disclosed
WO-2016179645-A1 4H-PYRAN COMPOUNDS AS INSULIN-REGULATED AMINOPEPTIDASE (IRAP) INHIBITORS MONASH UNIVERSITY (AU) 2016-11-17 — — WO disclosed
US-9410035-B2 Modified heterophasic polyolefin composition MILLIKEN & COMPANY (US) 2016-08-09 — — US disclosed
US-20160024289-A1 MODIFIED HETEROPHASIC POLYOLEFIN COMPOSITION MILLIKEN & COMPANY 2016-01-28 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210340547-A1 FIBROTIC TREATMENT MMP1, ENPEP, RNPEP KMT2A 2797/4885MEN1 4166/4885MAPT 3950/4885
US-20180170891-A1 4H-Pyran Compounds as Insulin-Regulated Aminopeptidase (IRAP) Inhibitors IAPP, ENPEP, DNPEP KMT2A 1612/4885MEN1 3983/4885MAPT 113/4885
US-11306066-B2 4H-pyran compounds as insulin-regulated aminopeptidase (IRAP) inhibitors IAPP, ENPEP, DNPEP KMT2A 1612/4885MEN1 3983/4885MAPT 113/4885
US-11834663-B2 Fibrotic treatment MMP1, ENPEP, RNPEP KMT2A 2797/4885MEN1 4166/4885MAPT 3950/4885
US-11078488-B2 Fibrotic treatment MMP1, ENPEP, RNPEP KMT2A 2797/4885MEN1 4166/4885MAPT 3950/4885
US-20240084308-A1 FIBROTIC TREATMENT MMP1, ENPEP, RNPEP KMT2A 2797/4885MEN1 4166/4885MAPT 3950/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.